164 related articles for article (PubMed ID: 24152603)
1. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability.
Lahu G; Facius A
Int J Clin Pharmacol Ther; 2013 Nov; 51(11):832-6. PubMed ID: 24152603
[TBL] [Abstract][Full Text] [Related]
2. Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD.
Watz H; Bagul N; Rabe KF; Rennard S; Alagappan VK; Román J; Facius A; Calverley PM
Int J Chron Obstruct Pulmon Dis; 2018; 13():813-822. PubMed ID: 29563781
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease.
Facius A; Marostica E; Gardiner P; Watz H; Lahu G
Clin Pharmacokinet; 2018 Aug; 57(8):1029-1038. PubMed ID: 29797235
[TBL] [Abstract][Full Text] [Related]
4. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A
Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
7. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
[TBL] [Abstract][Full Text] [Related]
8. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Rogliani P; Calzetta L; Cazzola M; Matera MG
Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
Taegtmeyer AB; Leuppi JD; Kullak-Ublick GA
Swiss Med Wkly; 2012; 142():w13628. PubMed ID: 22833385
[TBL] [Abstract][Full Text] [Related]
10. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
[TBL] [Abstract][Full Text] [Related]
11. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G
J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614
[TBL] [Abstract][Full Text] [Related]
12. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
[TBL] [Abstract][Full Text] [Related]
13. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast (Daliresp) for COPD.
Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
[No Abstract] [Full Text] [Related]
15. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
[TBL] [Abstract][Full Text] [Related]
16. Roflumilast for severe COPD?
Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic evaluation of roflumilast.
Lahu G; Nassr N; Hünnemeyer A
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
[TBL] [Abstract][Full Text] [Related]
18. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
Eckermann G; Lahu G; Nassr N; Bethke TD
J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799
[TBL] [Abstract][Full Text] [Related]
19. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
20. [Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
Michels G; Erdmann E; Pfister R
Dtsch Med Wochenschr; 2011 Nov; 136(44):2267-70. PubMed ID: 22028292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]